---
title: "NYC Series A in 2026: Data-Backed Benchmarks on Metrics, Valuations, and Timelines"
description: "A Series A in NYC 2026 typically requires $1-5M ARR (SaaS) or equivalent traction. Valuations range $40-150M post-money. Here's the data."
date: 2026-04-18T00:00:00.000Z
tags: ["vc-explainers", "nyc-startups", "startup-funding", "series-a"]
source: https://venturecapitaltracker.com/nyc-series-a-data-2025-metrics-valuation
---

# NYC Series A in 2026: Data-Backed Benchmarks on Metrics, Valuations, and Timelines

> A Series A in NYC 2026 typically requires $1-5M ARR (SaaS) or equivalent traction. Valuations range $40-150M post-money. Here's the data.

NYC Series A is a specific stage with specific expectations. Here's what the data says.

### The Series A baseline (2026)

- **Round size**: $10–25M typical; $25–50M for AI-native technical teams.
- **Post-money valuation**: $40–150M; AI-native can push $150M+.
- **Investment period**: Deploy over 18–24 months.
- **Board seat**: Lead investor takes board seat; some rounds include 1 independent.

### Metric benchmarks by sector (NYC Series A)

#### B2B SaaS
- **ARR**: $1–5M for most rounds; $3–10M for competitive.
- **Growth rate**: 100–200% YoY.
- **NRR**: > 110%.
- **Gross margin**: 70%+.
- **CAC payback**: under 24 months.
- **Burn multiple**: under 2x (net new ARR / net burn).

#### Fintech
- **Revenue or GTV**: $3M+ ARR or $100M+ GTV annualized.
- **Unit economics**: Clear path to profitability.
- **Regulatory posture**: No material compliance risk.
- **Customer profile**: Evidence of enterprise or SMB repeatability.

#### Marketplace
- **GMV**: $5M+ annualized.
- **Take rate**: Sustainable and growing.
- **Network density**: Strong in initial geography/category.
- **Cohort retention**: Improving over time.

#### Consumer
- **Revenue / DAU / MAU**: Depends on model.
- **Retention curves**: Flattening after initial drop.
- **CAC / LTV**: Clear positive economics.
- **Virality or repeat**: Organic growth component.

#### Health tech
- **Revenue or usage**: $1M+ ARR or 10K+ active users.
- **Regulatory readiness**: FDA pathway or HIPAA compliance clear.
- **Payer / provider mix**: Defined GTM path.

### Top NYC Series A leads in 2026

- **Primary Venture Partners** — for NYC-based companies at Series A.
- **Thrive Capital** — category-leader stage.
- **FirstMark Capital** — enterprise/consumer generalist.
- **Insight Partners (Growth)** — for more mature Series A ($8M+ ARR).
- **Bessemer Venture Partners** (NYC office) — SaaS strength.
- **Accel** (NYC presence) — growth-ready software.
- **Lightspeed Venture Partners** (NYC deals).
- **RRE Ventures**.
- **Greycroft** — consumer, fintech, media.

### The Series A process (NYC 2026)

**Weeks 0–4**: Prep, investor list, warm intros.
**Weeks 5–10**: First meetings (10–20), second meetings (5–10).
**Weeks 11–14**: Partner meetings (3–5), reference checks.
**Weeks 15–18**: Term sheet, negotiation.
**Weeks 19–24**: Close, legal, funding.

Total: 4–6 months from kickoff to funded for a competitive process.

### What fails NYC Series A rounds

1. **ARR but no retention**: High churn kills Series A even with growth.
2. **Founder conflicts**: Board-ready teams win; fragmenting teams don't.
3. **Cap table issues**: Unresolved SAFE stack, bad early grants.
4. **Regulatory shadow**: Compliance uncertainty disqualifies many fintech and health deals.
5. **TAM story weakness**: NYC investors demand bottoms-up TAM.

### Practical takeaway

- **Founders**: Start Series A conversations 6 months before your raise with 18 months of runway remaining.
- **Investors**: Series A pricing has stabilized post-2022; discipline on valuation is back.
- **LPs**: NYC Series A quality remains strong despite headline deal-count softness.

### Sources

1. AlleyWatch NYC VC reports: https://www.alleywatch.com/
2. Carta Q4 2025 VC performance: https://carta.com/data/vc-fund-performance-q4-2025/
3. Pitchbook-NVCA Q4 2025: https://nvca.org/wp-content/uploads/2026/01/q4-2025-pitchbook-nvca-venture-monitor.pdf

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.